What is the upside for Harrow Health (Harrow) stock?
On average, they expect Harrow Health's stock price to reach $15.08 in the next twelve months. This suggests a possible upside of 63.9% from the stock's current price.
What are analysts'price targets for Harrow Health's stock?
3 Wall Street analysts have issued 12-month price objectives for Harrow Health's shares. Their forecasts range from $14.25 to $16.00. On average, they expect Harrow Health's stock price to reach $15.08 in the next twelve months.
Will Harrow Health's earnings grow in the next year?
Earnings for Harrow Health are expected to grow by 65.63% in the coming year, from $0.32 to $0.53 per share. The P/E ratio of Harrow Health is -24.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Where can I buy shares of hrow?
Shares of HROW can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here.
Is Harrow Health a buy right now?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Harrow Health in the last year. There are currently 3 buy ratings for the...
When is Harrow Health's next earnings date?
Harrow Health is scheduled to release its next quarterly earnings announcement on Tuesday, August 9th 2022. View our earnings forecast for Harrow...
How were Harrow Health's earnings last quarter?
Harrow Health, Inc. (NASDAQ:HROW) released its earnings results on Thursday, March, 10th. The company reported ($0.01) EPS for the quarter, missing...
What price target forecast have analysts set for HROW?
3 Wall Street analysts have issued twelve-month price targets for Harrow Health's shares. Their forecasts range from $14.25 to $20.00. On average,...
Who are Harrow Health's key executives?
Harrow Health's management team includes the following people: Mr. Mark L. Baum J.D. , CEO & Chairman (Age 49, Pay $1.07M) Mr. Andrew R. Boll C....
Who are some of Harrow Health's key competitors?
Some companies that are related to Harrow Health include Rocket Pharmaceuticals (RCKT) , Phibro Animal Health (PAHC) , Nuvation Bio (NUVB) , Mo...
What other stocks do shareholders of Harrow Health own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Harrow Health investors own include NVIDIA (NVDA) , Aldey...
What is Harrow Health's stock symbol?
Harrow Health trades on the NASDAQ under the ticker symbol "HROW."
Who are Harrow Health's major shareholders?
Harrow Health's stock is owned by a number of retail and institutional investors. Top institutional investors include Renaissance Technologies LLC...
What is the official website of Harrow Health?
What is Harrow Health?
The official website for Harrow Health is www.harrowinc.com.
What is the P/E ratio of Harrow Health?
Harrow Health, Inc. engages in the development, production, and sale of innovative medications. It operates through the Pharmaceutical Compounding and Pharmaceutical Drug Development segments. The Pharmaceutical Compounding segment focuses on the operations of ImprimisRx business. The company was founded by Mark L. Baum and Robert J. Kammer in January 2006 and is headquartered in Nashville, TN.
Is Harrow Health a buy or sell company?
The P/E ratio of Harrow Health is -28.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Does Harrow Health pay dividends?
Harrow Health has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
What is Harrow Health?
Harrow Health does not currently pay a dividend.
Does Morningstar cover ratings?
Harrow Health Inc is an ophthalmology-focused pharmaceutical company. The company is specialized in the development, production, and sale of medications that offer competitive advantages and serve unmet needs in the marketplace. Its cornerstone of ophthalmology program consists of proprietary Dropless Therapy injectable and LessDrops topical formulations that are designed to address patient compliance issues and provide other compelling medical and economic benefits.
What is Harrow Health?
Companies with ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.
Who owns restricted shares of a company?
Harrow Health, Inc. engages in the development, production, and sale of innovative medications. It operates through the Pharmaceutical Compounding and Pharmaceutical Drug Development segments. The Pharmaceutical Compounding segment focuses on the operations of ImprimisRx...
How to calculate restricted stock?
Number of shares that are currently held by investors, including restricted shares owned by the company's officers and insiders as well as those held by the public.
Premium Research for HROW
To calculate, start with total shares outstanding and subtract the number of restricted shares. Restricted stock typically is that issued to company insiders with limits on when it may be traded. A company's dividend expressed as a percentage of its current stock price.
Company Summary
This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.